ImmunoBrain Announces Nature Medicine Publication and Late-Breaking AAIC 2026 Presentation for IBC-Ab002 in Early Alzheimer's Disease

ImmunoBrain announced that Phase 1b trial results for IBC-Ab002 have been published in Nature Medicine and will be presented as a late-breaking study at AAIC 2026 for early Alzheimer’s disease. The company said its investigational anti-PD-L1 antibody met the primary safety endpoint and produced encouraging fluid biomarker signals, including trends toward reductions associated with neuronal and synaptic damage. The randomized, double-blind Phase 1b study was conducted in 11 centers across the United Kingdom, Israel, and the Netherlands, using a short-lived checkpoint inhibitor over 48 weeks. ImmunoBrain highlighted reductions in cerebrospinal fluid biomarkers such as neurogranin, total Tau, and pTau181 at the end of the trial, along with target engagement and tolerability across doses. The therapy is described as part of a peripheral-immune checkpoint immunotherapy approach, tied to more than 25 years of research by Professor Michal Schwartz at the Weizmann Institute. The announcement is dated July 14, 2026.